Stockscreener 앱 받기
13.09
2.35%
0.30
시간 외 거래:
12.84
-0.25
-1.91%
전일 마감가:
$12.79
열려 있는:
$12.7
하루 거래량:
141.19K
Relative Volume:
0.58
시가총액:
$335.66M
수익:
-
순이익/손실:
$11.77M
주가수익비율:
22.63
EPS:
0.5785
순현금흐름:
$-19.23M
1주 성능:
+7.21%
1개월 성능:
-20.67%
6개월 성능:
-25.63%
1년 성능:
-66.00%
1일 변동 폭
$12.41
$13.10
1주일 범위
$11.87
$13.41
52주 변동 폭
$11.87
$48.31
Tourmaline Bio Inc Stock (TRML) Company Profile
명칭
Tourmaline Bio Inc
전화
646-481-9832
주소
27 WEST 24TH STREET, NEW YORK
TRML을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
13.09 | 335.66M | 0 | 11.77M | -19.23M | 0.5785 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 123.21B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 31.94B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.00B | 3.32B | -860.46M | -1.04B | -8.32 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-11-11 | 재확인 | H.C. Wainwright | Buy |
| 2023-12-15 | 개시 | Jefferies | Buy |
| 2023-12-04 | 재개 | H.C. Wainwright | Buy |
| 2023-11-17 | 개시 | Truist | Buy |
| 2023-10-31 | 개시 | Guggenheim | Buy |
| 2023-10-25 | 개시 | Piper Sandler | Overweight |
| 2022-10-20 | 개시 | H.C. Wainwright | Buy |
| 2022-07-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
모두보기
Tourmaline Bio Inc 주식(TRML)의 최신 뉴스
Truist maintains $74 target on Tourmaline Bio stock, reiterates buy By Investing.com - Investing.com UK
Financial Survey: X4 Pharmaceuticals (NASDAQ:XFOR) & Tourmaline Bio (NASDAQ:TRML) - Defense World
Lifesci Capital Predicts Tourmaline Bio FY2024 Earnings - Defense World
Tourmaline Bio (NASDAQ:TRML) Coverage Initiated by Analysts at Lifesci Capital - Defense World
Talaris Therapeutics stock hits 52-week low at $12.06 By Investing.com - Investing.com Australia
LifeSci Capital Initiates Coverage of Tourmaline Bio (TRML) with Outperform Recommendation - Nasdaq
Talaris Therapeutics stock hits 52-week low at $12.06 - Investing.com
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
We Tested Over 25 Curling Irons. These 13 Are the Best - MarieClaire.com
Vaxcyte (NASDAQ:PCVX) & Tourmaline Bio (NASDAQ:TRML) Financial Review - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $54.00 Average PT from Brokerages - MarketBeat
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Average Recommendation of "Buy" by Analysts - MarketBeat
StockNews.com Downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) to Buy - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Average Recommendation of “Buy” by Analysts - Defense World
ClearOne (NASDAQ:CLRO) Earns Hold Rating from Analysts at StockNews.com - Defense World
Broadway Financial (NASDAQ:BYFC) Now Covered by StockNews.com - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Short Interest Up 16.3% in January - MarketBeat
TrueBlue (TBI) Expected to Announce Earnings on Wednesday - Armenian Reporter
Andersons (ANDE) Projected to Post Quarterly Earnings on Tuesday - Defense World
Leerink Partnrs Comments on Tourmaline Bio FY2024 Earnings - MarketBeat
Leerink Partnrs Weighs in on Tourmaline Bio FY2029 Earnings - MarketBeat
Bleakley Financial Group LLC Purchases 110 Shares of Choice Hotels International, Inc. (NYSE:CHH) - Defense World
In the crowded cardio space, it’s David vs. Goliath for small biotechs - PharmaVoice
Jennison Associates LLC Trims Stake in Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat
Tourmaline Bio Inc (TRML) Stock Showcases -13.66% 20-Day Moving Average - The News Heater
TRML’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Solventum Corp (SOLV) Shares Down Despite Recent Market Volatility - The News Heater
Tourmaline Bio Inc (TRML) Becoming More Attractive for Investors - Knox Daily
In the Green: JBDI Holdings Ltd (JBDI) Closes at 0.65, Up/Down 11.02 from Previous Day - The Dwinnex
Closing Bell Recap: E.W. Scripps Co (SSP) Ends at 1.88, Reflecting a 6.82 Upturn - The Dwinnex
Post-Trade Analysis: Celldex Therapeutics Inc (CLDX) Slides -2.11, Closing at 23.15 - The Dwinnex
Market Insights: Avidity Biosciences Inc (RNA)’s Notable Gain of 4.32, Closing at 33.34 - The Dwinnex
Daily Market Movement: Tourmaline Bio Inc (TRML) Sees a 6.37 Increase, Closing at 16.53 - The Dwinnex
Keeping an Eye on Entegris Inc (ENTG) After Insider Trading Activity - Knox Daily
Potential Price Increase for Monster Beverage Corp (MNST) After Recent Insider Activity - Knox Daily
Recent Insider Activity Suggests Potential Gains for Vita Coco Company Inc (COCO) - Knox Daily
Jefferies Upgrades Relay Therapeutics Inc (RLAY) to a Buy from a Hold - Knox Daily
Short Interest in Tourmaline Bio, Inc. (NASDAQ:TRML) Rises By 26.8% - MarketBeat
JPMorgan Chase & Co. Acquires 2,100 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Graves Ophthalmopathy Market to Expand Significantly by 2034, States DelveInsight Report | Novartis, AdvanceCor, Apitope, Worg Pharma, AV7 Limited - The Globe and Mail
Graves Ophthalmopathy Market to Expand Significantly by 2034, - openPR
Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference - Marketscreener.com
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Graves' Disease Market Size in the 7MM was ~USD 4,400 million - openPR
Cantor Fitzgerald Estimates Tourmaline Bio FY2025 Earnings - Defense World
Brokers Issue Forecasts for Tourmaline Bio FY2025 Earnings - MarketBeat
Barclays PLC Purchases Shares of 73,897 Mitsubishi UFJ Financial Group, Inc. (NYSE:MUFG) - Defense World
Tourmaline Bio Inc (TRML) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tourmaline Bio Inc 주식 (TRML) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kulkarni Sandeep Chidambar | CEO |
Aug 16 '24 |
Buy |
13.79 |
5,221 |
71,998 |
5,221 |
0.22%
0.81%
자본화:
|
볼륨(24시간):